StockData
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. (INKT) stock

INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$9.29−0.06 (-0.70%)

Close on Nov 17, 2026Market cap $47.38MP/E –Yield –

MiNK Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

MiNK Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.75M, up 13.9% year over year. For fiscal 2025 it was $5.76M, down 9.1% from the year before. The highest annual figure on record is $23.12M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.76M-9.1%
FY2024Dec 31, 2024$6.34M-59.1%
FY2023Dec 31, 2023$15.49M-33.0%
FY2022Dec 31, 2022$23.12M+65.5%
FY2021Dec 31, 2021$13.97M+46.9%
FY2020Dec 31, 2020$9.51M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.89M+2.6%
Q1 FY2026Mar 31, 2026$1.20M-4.6%
Q4 FY2025Dec 31, 2025$1.51M+7.6%
Q3 FY2025Sep 30, 2025$1.14M+111.4%
Q2 FY2025Jun 30, 2025$1.84M-0.0%
Q1 FY2025Mar 31, 2025$1.26M-50.5%
Q4 FY2024Dec 31, 2024$1.41M-57.5%
Q3 FY2024Sep 30, 2024$540.64K-84.2%
Q2 FY2024Jun 30, 2024$1.84M-59.6%
Q1 FY2024Mar 31, 2024$2.55M-39.2%
Q4 FY2023Dec 31, 2023$3.31M-43.0%
Q3 FY2023Sep 30, 2023$3.43M-44.3%
Q2 FY2023Jun 30, 2023$4.56M-22.4%
Q1 FY2023Mar 31, 2023$4.19M-20.5%
Q4 FY2022Dec 31, 2022$5.81M+47.1%
Q3 FY2022Sep 30, 2022$6.15M+84.4%
Q2 FY2022Jun 30, 2022$5.88M+63.9%
Q1 FY2022Mar 31, 2022$5.28M+70.4%
Q4 FY2021Dec 31, 2021$3.95M+401.4%
Q3 FY2021Sep 30, 2021$3.33M+33.2%
Q2 FY2021Jun 30, 2021$3.58M–
Q1 FY2021Mar 31, 2021$3.10M–
Q4 FY2020Dec 31, 2020$787.82K–
Q3 FY2020Sep 30, 2020$2.50M–

More MiNK Therapeutics figures

See a number that looks wrong?